Coronary and Structural Interventions - Transcatheter Aortic Valve Replacement

Conditions

Aortic Valve Stenosis

Brief summary

To evaluate the long-term results after transcatheter aortic valve replacement

Detailed description

Patients with transcatheter aortic valve replacement are followed for 5 years to demonstrate efficacy and safety.

Seeger J, Gonska B, Rottbauer W, Wöhrle J.

2017-06-2222 citations

10.1007/s12928-017-0477-6

Outcome With the Repositionable and Retrievable Boston Scientific Lotus Valve Compared With the Balloon-Expandable Edwards Sapien 3 Valve in Patients Undergoing Transfemoral Aortic Valve Replacement

Julia Seeger, Birgid Gonska, Wolfgang Rottbauer, Jochen Wöhrle

Circulation Cardiovascular Interventions2017-06-0120 citations

10.1161/circinterventions.116.004670

Predictors for permanent pacemaker implantation in patients undergoing transfemoral aortic valve implantation with the Edwards Sapien 3 valve.

Gonska B, Seeger J, Keßler M, von Keil A, Rottbauer W, Wöhrle J.

2017-03-1049 citations

10.1007/s00392-017-1093-2

Outcome of Patients with Mixed Aortic Valve Disease Undergoing Transfemoral Aortic Valve Replacement

Julia Seeger, Birgid Gonska, Johannes Mörike, Wolfgang Rottbauer, Jochen Wöhrle

Structural Heart2017-03-0114 citations

10.1080/24748706.2017.1348648

The balloon-expandable Edwards Sapien 3 valve is superior to the self-expanding Medtronic CoreValve in patients with severe aortic stenosis undergoing transfemoral aortic valve implantation.

Gonska B, Seeger J, Baarts J, Rodewald C, Scharnbeck D, Rottbauer W, Wöhrle J.

2016-09-0713 citations

10.1016/j.jjcc.2016.08.008

Impact of suture mediated femoral access site closure with the Prostar XL compared to the ProGlide system on outcome in transfemoral aortic valve implantation.

Seeger J, Gonska B, Rodewald C, Rottbauer W, Wöhrle J.

2016-08-1731 citations

10.1016/j.ijcard.2016.08.193

Transfemoral aortic valve implantation with the repositionable Lotus valve for treatment of patients with symptomatic severe aortic stenosis: results from a single-centre experience

Jochen Wöhrle, Birgid Gonska, Christoph Rodewald, Julia Seeger, Dominik Scharnbeck et al. (6 authors)

EuroIntervention2016-08-0114 citations

10.4244/eijv12i6a124

Transfemoral Aortic Valve Implantation with the New Edwards Sapien 3 Valve for Treatment of Severe Aortic Stenosis—Impact of Valve Size in a Single Center Experience

Jochen Wöhrle, Birgid Gonska, Christoph Rodewald, Julia Seeger, Dominik Scharnbeck et al. (6 authors)

PLoS ONE2016-03-2225 citations

10.1371/journal.pone.0151247

Interventions

DEVICECE certified transcatheter ( aortic valve replacement)

Patients receive a transcatheter aortic valve replacement with CE certified transcatheter aortic valves.

Study design

Allocation

NA

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Intervention model description

TAVR

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

No

Inclusion criteria

* aortic valve stenosis * transcatheter aortic valve replacement

Exclusion criteria

* no written informed consent

Design outcomes

Primary

Measure	Time frame
Major adverse cerebral and cardiac events.	1-5 years

Countries

Germany

Outcome results

None listed